<DOC>
	<DOCNO>NCT00550901</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , dexrazoxane cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may help kill tumor cell . PURPOSE : This phase I trial study side effect best dose dexrazoxane give together cisplatin treat patient advance solid tumor .</brief_summary>
	<brief_title>Dexrazoxane Cisplatin Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - To establish maximum tolerated dose 96-hour continuous infusion dexrazoxane hydrochloride single-dose , one-hour infusion cisplatin patient advance solid tumor . - To determine pharmacokinetics dexrazoxane hydrochloride cisplatin give concurrently . - To describe toxicity infusional dexrazoxane hydrochloride cisplatin give combination . OUTLINE : Patients receive dexrazoxane hydrochloride IV continuously 96 hour begin day 1 cisplatin IV 1 hour day 3 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Blood collect periodically course one pharmacokinetic study . DNA isolate sample also analyze oxidative DNA damage gas chromatography/mass spectrometry . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Histologically confirm advanced , incurable cancer unresponsive prior chemotherapy regimens standard chemotherapy regimen exist History brain metastasis allow control radiotherapy surgery patient 's neurological status stable Concurrent corticosteroid allow long require dose stable decrease Not eligible high priority study PATIENT CHARACTERISTICS : Inclusion criterion : Karnofsky performance status 60100 % Life expectancy ≥ 12 week ANC ≥ 2,000/mm³ Platelet count ≥ 100,000/mm³ Serum creatinine ≤ 1.6 mg/dL OR creatinine clearance ≥ 60 mL/min Bilirubin ≤ 1.5 mg/dL SGOT &lt; 3 time upper limit normal Recovered recent severe infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Exclusion criterion : Patients nonmalignant intercurrent illness ( e.g. , cardiovascular , pulmonary , neurologic ) either poorly control currently available treatment , severity investigator deem unwise enter patient onto study PRIOR CONCURRENT THERAPY : Inclusion criterion : See Disease Characteristics At least 4 week since prior radiotherapy chemotherapy recover Recovered prior major surgery Exclusion criterion : Concurrent treatment severe infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>